Board of Scientific Counselors, National Institute for Occupational Safety and Health, 14371-14372 [2023-04701]
Download as PDF
Federal Register / Vol. 88, No. 45 / Wednesday, March 8, 2023 / Notices
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
Matters to be Considered: The agenda
will include discussions on the
following: NIOSH Program Update;
Department of Labor Program Update;
Department of Energy Program Update;
SEC Petitions Update; Procedures
Review Finalization/Document
Approvals; Savannah River Site
Workgroup Update, and a Board Work
Session. Agenda items are subject to
change as priorities dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
(Authority: 5 U.S.C. 1001 et. seq.)
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2023–04700 Filed 3–7–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2023–0015; NIOSH 278]
Board of Scientific Counselors,
National Institute for Occupational
Safety and Health
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with regulatory
provisions, the Centers for Disease
Control and Prevention announces the
following meeting of the Board of
Scientific Counselors, National Institute
for Occupational Safety and Health
(BSC, NIOSH). This is a virtual meeting.
It is open to the public, limited only by
the number of web conference lines (500
web conference lines are available).
Time will be available for public
comment.
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
The meeting will be held on
April 21, 2023, from 10 a.m. to 3 p.m.,
EDT.
DATES:
VerDate Sep<11>2014
16:48 Mar 07, 2023
Jkt 259001
Written comments must be received
on or before April 14, 2023.
ADDRESSES: If you wish to attend the
meeting, please register at the NIOSH
website at https://www.cdc.gov/niosh/
bsc/ or by telephone at (202) 245–0649
no later than April 14, 2023.
You may submit comments, identified
by Docket No. CDC–2023–0015;
NIOSH–278 by either of the methods
listed below. CDC does not accept
comments by email.
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Ms. Sherri Diana, NIOSH
Docket Office, National Institute for
Occupational Safety and Health, 1090
Tusculum Avenue, Mailstop C–34,
Cincinnati, Ohio 45226. Attn: Docket
No. CDC–2023–0015; NIOSH–278.
Instructions: All submissions received
must include the Agency name and
docket number. Docket number CDC–
2023–0015; NIOSH–278 will close April
14, 2023.
FOR FURTHER INFORMATION CONTACT:
Maria Strickland, M.P.H., Designated
Federal Officer, BSC, NIOSH, CDC,
Patriots Plaza 1, 395 E Street SW, Suite
9200, Washington, DC 20201;
Telephone: (202) 245–0649; Email:
MStrickland2@cdc.gov.
SUPPLEMENTARY INFORMATION:
Background: The Secretary of Health
and Human Services, the Assistant
Secretary for Health, and by delegation
the Director, Centers for Disease Control
and Prevention, are authorized under
Sections 301 and 308 of the Public
Health Service Act to conduct directly,
or by grants or contracts, research,
experiments, and demonstrations
relating to occupational safety and
health and to mine health.
Purpose: The Board of Scientific
Counselors, National Institute for
Occupational Safety and Health (BSC,
NIOSH) provides advice to the Director,
National Institute for Occupational
Safety and Health, on NIOSH research
and prevention programs. The Board
also provides guidance on the Institute’s
research activities related to developing
and evaluating hypotheses,
systematically documenting findings,
and disseminating results. In addition,
the Board evaluates the degree to which
the activities of NIOSH: (1) conform to
those standards of scientific excellence
appropriate for federal scientific
institutions in accomplishing objectives
in occupational safety and health; (2)
address currently relevant needs in the
fields of occupational safety and health
either alone or in conjunction with
other known activities inside and
outside of NIOSH; and (3) produce their
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
14371
intended results in addressing
important research questions in
occupational safety and health, both in
terms of applicability of the research
findings and dissemination of the
findings.
Matters to be Considered: The agenda
for the meeting addresses Per- and
Polyfluoroalkyl Substances and
Occupational Safety and Health
Economics. Agenda items are subject to
change as priorities dictate.
The agenda is also posted on the
NIOSH website at https://www.cdc.gov/
niosh/bsc/.
Public Participation
Written Public Comment: Written
comments will be accepted per the
instructions provided in the addresses
section above. Comments received in
advance of the meeting are part of the
public record and are subject to public
disclosure. Written comments will be
included in the official record of the
meeting. Do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near-duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written comments received by April
14, 2023, will be provided to the Board
prior to the meeting.
Oral Public Comment: The public is
welcome to participate during the
public comment period, from 1:30 p.m.
to 1:45 p.m., EDT, April 21, 2023. Each
commenter will be provided up to five
minutes for comment. A limited number
of time slots are available and will be
assigned on a first-come, first-served
basis. Members of the public who wish
to address the BSC, NIOSH are
requested to contact the Designated
Federal Officer for scheduling purposes
(see FOR FUTHER INFORMATION CONTACT
above).
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
E:\FR\FM\08MRN1.SGM
08MRN1
14372
Federal Register / Vol. 88, No. 45 / Wednesday, March 8, 2023 / Notices
Prevention and the Agency for Toxic
Substances and Disease Registry.
Prevention and the Agency for Toxic
Substances and Disease Registry.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
Centers for Disease Control and
Prevention
[FR Doc. 2023–04701 Filed 3–7–23; 8:45 am]
[FR Doc. 2023–04696 Filed 3–7–23; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—CE23–008,
Research Grants To Develop and
Validate a Prognostic Tool of Mental
Health Sequelae After Traumatic Brain
Injury for Adolescent Patients (U01);
Amended Notice of Closed Meeting
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP)—CE23–
008, Research Grants to Develop and
Validate a Prognostic Tool of Mental
Health Sequelae After Traumatic Brain
Injury for Adolescent Patients (U01),
March 14, 2023, 8:30 a.m., EDT–5:30
p.m., EDT, Web Conference, in the
original FRN. The meeting was
published in the Federal Register on
January 20, 2023, Volume 88, Number
13, page/s/ 3743.
The meeting is being amended to
begin the meeting later and should read
as follows:
Date: March 14, 2023.
Time: 10:00 a.m.–6:00 p.m. (EDT).
Place: Videoconference.
The meeting is closed to the public.
lotter on DSK11XQN23PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
Carlisha Gentles, PharmD, BCPS,
CDCES, Scientific Review Officer,
National Center for Injury Prevention
and Control, CDC, 4770 Buford Highway
NE, Mailstop F–63, Atlanta, Georgia
30341, Telephone: (770)488–1504;
Email: CGentles@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
VerDate Sep<11>2014
16:48 Mar 07, 2023
Jkt 259001
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—RFA–TS–23–
001: Identify and Evaluate Potential
Risk Factors for Amyotrophic Lateral
Sclerosis (ALS); Amended Notice of
Closed Meeting
Notice is hereby given of a change in
the meeting of the
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—RFA–TS–23–
001: Identify and Evaluate Potential
Risk Factors for Amyotrophic Lateral
Sclerosis (ALS); April 11, 2023, 8:30
a.m.–5:30 p.m., EDT, Videoconference,
in the original FRN. The meeting was
published in the Federal Register on
January 18, 2023, Volume 88, Number
11, page 2921.
The meeting is being amended to
begin the meeting later and should read
as follows:
Date: April 11, 2023.
Time: 10:00 a.m.–5:00 p.m. (EDT).
Place: Videoconference.
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT:
Carlisha Gentles, PharmD, BCPS,
CDCES, Scientific Review Officer,
National Center for Injury Prevention
and Control, CDC, 4770 Buford Highway
NE, Mailstop F–63, Atlanta, Georgia
30341, Telephone (770)488–1504,
Email: CGentles@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2023–04699 Filed 3–7–23; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—RFA–PS23–
001, Increasing PrEP Use Among
Disproportionately Affected
Populations in the United States and
RFA–PS23–003, Exploring Preferences
for Long-Acting Antiretroviral
Therapies (LA–ART) in a CommunityBased Sample of Priority Populations
Living With HIV Who Are
Disproportionately Affected; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP)—RFA–
PS23–001, Increasing PrEP Use Among
Disproportionately Affected Populations
in the United States and RFA–PS23–
003, Exploring Preferences for LongActing Antiretroviral Therapies (LA–
ART) in a Community-Based Sample of
Priority Populations Living with HIV
Who are Disproportionately Affected,
May 11–12, 2023, 10 a.m.–5 p.m., EDT,
Teleconference, Centers for Disease
Control and Prevention, Room 1077, 8
Corporate Blvd., Atlanta, GA 30329, in
the original FRN. The meeting was
published in the Federal Register on
February 13, 2023, Volume 88, Number
29, page/s/ 9288–9289.
The meeting is being amended to
change the title of RFA–PS23–001,
Increasing PrEP Use Among
Disproportionately Affected Populations
in the United States to RFA–PS23–001,
Increasing PrEP Use Among Black
Cisgender Women in the United States
(HerPrEP) and to remove RFA–PS23–
003, Exploring Preferences for LongActing Antiretroviral Therapies (LA–
ART) in a Community-Based Sample of
Priority Populations Living with HIV
Who are Disproportionately Affected
and replace with RFA–PS23–005,
Expanding Rapid Initiation of
Antiretroviral Therapy in Nontraditional Settings: Emergency
Department. The date of the
teleconference will also change and
should read as follows:
Date: May 24–25, 2023.
Place: Teleconference, Centers for
Disease Control and Prevention, Room
1077, 8 Corporate Blvd., Atlanta, GA
30329.
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, National
E:\FR\FM\08MRN1.SGM
08MRN1
Agencies
[Federal Register Volume 88, Number 45 (Wednesday, March 8, 2023)]
[Notices]
[Pages 14371-14372]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-04701]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2023-0015; NIOSH 278]
Board of Scientific Counselors, National Institute for
Occupational Safety and Health
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with regulatory provisions, the Centers for
Disease Control and Prevention announces the following meeting of the
Board of Scientific Counselors, National Institute for Occupational
Safety and Health (BSC, NIOSH). This is a virtual meeting. It is open
to the public, limited only by the number of web conference lines (500
web conference lines are available). Time will be available for public
comment.
DATES: The meeting will be held on April 21, 2023, from 10 a.m. to 3
p.m., EDT.
Written comments must be received on or before April 14, 2023.
ADDRESSES: If you wish to attend the meeting, please register at the
NIOSH website at https://www.cdc.gov/niosh/bsc/ or by telephone at
(202) 245-0649 no later than April 14, 2023.
You may submit comments, identified by Docket No. CDC-2023-0015;
NIOSH-278 by either of the methods listed below. CDC does not accept
comments by email.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Ms. Sherri Diana, NIOSH Docket Office, National
Institute for Occupational Safety and Health, 1090 Tusculum Avenue,
Mailstop C-34, Cincinnati, Ohio 45226. Attn: Docket No. CDC-2023-0015;
NIOSH-278.
Instructions: All submissions received must include the Agency name
and docket number. Docket number CDC-2023-0015; NIOSH-278 will close
April 14, 2023.
FOR FURTHER INFORMATION CONTACT: Maria Strickland, M.P.H., Designated
Federal Officer, BSC, NIOSH, CDC, Patriots Plaza 1, 395 E Street SW,
Suite 9200, Washington, DC 20201; Telephone: (202) 245-0649; Email:
MStric[email protected].
SUPPLEMENTARY INFORMATION:
Background: The Secretary of Health and Human Services, the
Assistant Secretary for Health, and by delegation the Director, Centers
for Disease Control and Prevention, are authorized under Sections 301
and 308 of the Public Health Service Act to conduct directly, or by
grants or contracts, research, experiments, and demonstrations relating
to occupational safety and health and to mine health.
Purpose: The Board of Scientific Counselors, National Institute for
Occupational Safety and Health (BSC, NIOSH) provides advice to the
Director, National Institute for Occupational Safety and Health, on
NIOSH research and prevention programs. The Board also provides
guidance on the Institute's research activities related to developing
and evaluating hypotheses, systematically documenting findings, and
disseminating results. In addition, the Board evaluates the degree to
which the activities of NIOSH: (1) conform to those standards of
scientific excellence appropriate for federal scientific institutions
in accomplishing objectives in occupational safety and health; (2)
address currently relevant needs in the fields of occupational safety
and health either alone or in conjunction with other known activities
inside and outside of NIOSH; and (3) produce their intended results in
addressing important research questions in occupational safety and
health, both in terms of applicability of the research findings and
dissemination of the findings.
Matters to be Considered: The agenda for the meeting addresses Per-
and Polyfluoroalkyl Substances and Occupational Safety and Health
Economics. Agenda items are subject to change as priorities dictate.
The agenda is also posted on the NIOSH website at https://www.cdc.gov/niosh/bsc/.
Public Participation
Written Public Comment: Written comments will be accepted per the
instructions provided in the addresses section above. Comments received
in advance of the meeting are part of the public record and are subject
to public disclosure. Written comments will be included in the official
record of the meeting. Do not include any information in your comment
or supporting materials that you consider confidential or inappropriate
for public disclosure. If you include your name, contact information,
or other information that identifies you in the body of your comments,
that information will be on public display. CDC will review all
submissions and may choose to redact, or withhold, submissions
containing private or proprietary information such as Social Security
numbers, medical information, inappropriate language, or duplicate/
near-duplicate examples of a mass-mail campaign. CDC will carefully
consider all comments submitted into the docket.
Written comments received by April 14, 2023, will be provided to
the Board prior to the meeting.
Oral Public Comment: The public is welcome to participate during
the public comment period, from 1:30 p.m. to 1:45 p.m., EDT, April 21,
2023. Each commenter will be provided up to five minutes for comment. A
limited number of time slots are available and will be assigned on a
first-come, first-served basis. Members of the public who wish to
address the BSC, NIOSH are requested to contact the Designated Federal
Officer for scheduling purposes (see FOR FUTHER INFORMATION CONTACT
above).
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and
[[Page 14372]]
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-04701 Filed 3-7-23; 8:45 am]
BILLING CODE 4163-18-P